May 19, 2016
Supplements
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Although lung cancer remains the leading cause of cancer mortality—outweighing prostate, breast, and colon cancer combined—advances in treatment are improving patient outcomes and decreasing mortality.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
For many patients with non–small-cell lung cancer (NSCLC), immunotherapy is now becoming the standard of care. Immunotherapy given as monotherapy or in combination with other agents has contributed to promising results in NSCLC, with the earliest results observed in 2015 with nivolumab, and subsequently leading to FDA approval of 6 agents.
Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
The American Cancer Society estimates 236,740 new cases of lung cancer and 130,180 deaths from lung cancer in 2022, second only to prostate cancer in men and breast cancer in women.1
Novel BCMA-Targeting Bispecific T-cell Engagers: Emerging Role in Advanced MM
Multiple myeloma (MM) is a malignancy of plasma cells that accumulate in the bone marrow and/or extramedullary sites, leading to complications such as renal failure, bone destruction, and hypercalcemia.
Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with advanced non–small-cell lung cancer (NSCLC) by demonstrating significantly better outcomes and tolerability than conventional chemotherapy.
2022 Midyear Review: Non–Small-Cell Lung Cancer
We are pleased to provide highlights of important and potentially practice-changing developments in immunotherapy of non–small-cell lung cancer (NSCLC) presented at the 2022 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). In this print supplement, we will summarize pivotal clinical data that were presented on immune checkpoint inhibitor therapy of NSCLC at both of these key meetings.
A total of 25 data presentations from AACR 2022 and ASCO 2022 are summarized in this resource. We hope that the information reviewed here can be applied to clinical practice and offers valuable insights into the important progress that is being made in the care of patients with NSCLC.
2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments
Supported through funding from
Dual immunotherapy for cancer has been one of the most successful modes of treatment researched and developed in recent years, with many new studies having been completed this past year. Immunotherapy has been used in the past for oncological treatments with monotherapy and in combination with chemotherapy; these new studies provide data on the success of combinations of various monoclonal antibodies for treatment of solid tumors.
These major research advances have been compiled from presentations at the 2021 American Society of Clinical Oncology and 2021 European Society for Medical Oncology annual meetings, in addition to manuscripts published in key journals. This year in review summarizes data on these important and innovative therapies.
2021 Midyear Review: Non–Small-Cell Lung Cancer
Supported through funding from
This material is divided into the following topic areas:
Faculty Perspectives: Current Guidelines and Emerging Treatments in Nonmetastatic NSCLC
TLG1823
Supported through funding from
Highlights
Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum
Highlights
- The combination of cytogenetic information provided by karyotype analysis and the identification of molecular abnormalities is crucial to the management of acute myeloid leukemia (AML), as it may inform treatment strategies and it provides invaluable prognostic information regarding remission rates, relapse risk, and overall survival outcomes
- FLT3-ITD, ASXL1, RUNX1, TP53, and KIT mutations have been linked to poor prognosis
- While the evidence is mixed for the prognostic value of FLT3-TKD (~7% of patients), numerous studies have demonstrated the negative prognostic influence of FLT3-ITD (~25% of patients)
- AML is characterized by clonal evolution, and FLT3 mutation status may change between initial treatment and relapse. It may be important to perform genetic testing multiple times over the care continuum
Best Practice in Immuno-Oncology Biomarker Testing – DECEMBER 2018 | Part 4 of a 4-Part Series
Highlights
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Highlights
Best Practice in Immuno-Oncology Biomarker Testing – OCTOBER 2018 | Part 3 of a 4-Part Series
Highlights
Best Practices in Immuno-Oncology Biomarker Testing – SEPTEMBER 2018 | Part 2 of a 4-Part Series
Highlights
Faculty Perspectives: Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology | Part 2 of a 4-Part Series
Highlights
Best Practices in Immuno-Oncology Biomarker Testing – AUGUST 2018 | Part 1 of a 4-Part Series
Highlights
Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series
Highlights
Mechanism of Action Magnifier – 2016 Desk Reference
Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.
Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?
- Review of the Initial Results from Basket Trials
- Implications of Initial Results in Patients with Metastatic Cancer and Diagnostic Ambiguity
- Improving Diagnostic Certainty: The Role of Molecular Assays in Challenging Cases
- Performance of the CancerTYPE IDÂ Molecular Classifier
Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
- Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
- Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
- PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
- Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-Îł receptor signaling